FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ALTSHULER DAVID (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE (Street) BOSTON MA 02210					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 05/15/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)							(Chec	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, Global Research and CSO S. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Sta	ate) (2	Zip)															
		Table	I - No	n-Derivat	ive S	Secur	ities	Acqı	iired,	Dis	posed	of, o	Ben	eficially	/ Own	ed		
1. Title of Security (Instr. 3)			Dat	2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,					Secur Benef Owne Follow	icially d ving	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	e v	Am	ount	(A) or (D)	Price			rted action(s) 3 and 4)		
Common	Stock		0	5/15/2020				S ⁽¹⁾			2	D	\$27	4.98(2)(3)	2	8,982	D	
Common Stock				05/15/2020				S ⁽¹⁾			4	D	\$27	\$276.44(3)(4)		28,978		
Common Stock			0	05/15/2020				S ⁽¹⁾			5	D	\$27	9.48(3)(5)	2	8,973	D	
Common Stock			0	05/15/2020				S ⁽¹⁾			9	D	\$28	\$280.47(3)(6)		8,964	D	
Common Stock				05/15/2020				S ⁽¹⁾			4	D	\$281.55 ⁽³⁾⁽⁷⁾		2	8,960	D	
Common Stock			0	05/15/2020				S ⁽¹⁾		6 D \$282.		2.77(3)(8)	7 ⁽³⁾⁽⁸⁾ 28,954		D			
Common Stock			0	05/15/2020				S ⁽¹⁾	S ⁽¹⁾		3	D \$283.74		3.74(3)(9)	⁽⁹⁾ 28,951		D	
Common Stock			0	05/15/2020				S ⁽¹⁾	.1)		5	D	\$284.98(3)(10)		28,946		D	
Common Stock			0	05/15/2020				S ⁽¹⁾			10	D	D \$286.1		28,936		D	
Common Stock			0	05/15/2020				S ⁽¹⁾	S ⁽¹⁾		15	D	\$287.19(3)		28,921		D	
Common Stock 05/15/20				5/15/2020)			S ⁽¹⁾			19	D \$288.05		3.05 ⁽³⁾⁽¹³⁾	28,902		D	
		Tal		Derivativ											Owne	d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Executi if any	A. Deemed eccution Date,		action (Instr.	5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5	nber (lative ities red sed 3, 4	er 6. Date E Expiratio (Month/D		xercisable and n Date		Fitle and nount of curities derlying rivative curity (I nd 4)	i 8. De Se j (in	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
Evnlanation	n of Respons				Code	v	(A)		Date Exercisa	ıble	Expiratio Date	n Tit	or Nur of	ount nber ires				

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Altshuler's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$274.98 (range \$274.67 to \$275.28).
- 3. Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$276.44 (range \$276.23 to \$276.75).
- 5. Open market sales reported on this line occurred at a weighted average price of \$279.48 (range \$278.84 to \$279.82).
- 6. Open market sales reported on this line occurred at a weighted average price of \$280.47 (range \$280.21 to \$280.68).
- 7. Open market sales reported on this line occurred at a weighted average price of \$281.55 (range \$281.24 to \$282.20).
- 8. Open market sales reported on this line occurred at a weighted average price of \$282.77 (range \$282.36 to \$283.28).
- 9. Open market sales reported on this line occurred at a weighted average price of \$283.74 (range \$283.44 to \$284.05).
- 10. Open market sales reported on this line occurred at a weighted average price of \$284.98 (range \$284.56 to \$285.43).
- 11. Open market sales reported on this line occurred at a weighted average price of \$286.12 (range \$285.60 to \$286.43).
- 12. Open market sales reported on this line occurred at a weighted average price of \$287.19 (range \$286.61 to \$287.60).
- 13. Open market sales reported on this line occurred at a weighted average price of \$288.05 (range \$287.70 to \$288.47).

<u>Fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.